KRAS and neoplasm: Increasing evidence shows that KRAS mutations in tumours not only dedicate the intrinsic characteristics of tumours, such as survival and proliferation but also form a tumour microenvironment (TME), especially affecting immune cells in the TME and eventually resulting in tumour progression and immune escape80,81.